C3.ai Stock Is Falling Thursday: What’s Going On?

C3.ai Inc (NYSE: AI) shares are trading lower Thursday on the heels of the company's quarterly results. Here's a look at key metrics from the quarter.

C3.ai Inc (NYSE:AI) shares are trading lower Thursday on the heels of the company’s quarterly results. Here’s a look at key metrics from the quarter.

  • Q1 Revenue: $72.4 million beat estimates of $71.59 million
  • Q1 EPS: loss of 9 cents beat estimates for a loss of 17 cents

“It is difficult to describe the scale of the increasing interest that we are seeing globally in enterprise AI adoption,” said Thomas Siebel, CEO of C3.ai.

“We are experiencing strong traction with our enterprise AI applications and especially C3 Generative AI.”

Guidance: C3.ai sees fiscal second-quarter revenue in the range of $72 million to $76.5 million versus estimates of $73.81 million. The company expects full-year revenue to be between $295 million and $320 million versus estimates of $308.2 million.

AI Update: C3.ai also announced the launch of C3 Generative AI Suite, which features 28 domain-specific generative AI offerings. The AI solutions can be operated on the customer’s platform of choice including, AWS, Google’s Cloud platform and Microsoft Azure. 

“The market interest that we are seeing in C3 Generative AI is staggering. The addressable market is unknowably large and appears to more than double our Enterprise AI market opportunity,” Siebel added. 

See Also: Dell Becomes One Of The Early Generative AI Winners

AI Price Action: C3.ai shares were down 13.5% at $27.22 at the time of writing, according to Benzinga Pro.

Photo: Vicki Hamilton from Pixabay.

Total
0
Shares
Related Posts
Read More

Calliditas Therapeutics Announces That The U.S. Patent And Trademark Office Issued Patent #11896719, Entitled “New Pharmaceutical Compositions,” On January 24, 2024 With Validity As Of Today, February 13, 2024

Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no. 11896719, entitled "New Pharmaceutical

CALT

Read More

Flip Your Pre-Roll: 50-50 Odds It’s Crafted By This Weed Company Dominating Half Of Canada’s Market

In Canada, there's a 50-50 chance that the pre-roll lighting up your day is made by one company: Decibel. Infused pre-rolls have ignited a fiery growth trend, with Decibel stoking the flames and reigning supreme as the king of pre-rolls.

DBCCF